Ansuvimab: First Approval

Ansuvimab (ansuvimab-zykl; EBANGA (TM)) is a human monoclonal antibody developed by Ridgeback Biotherapeutics, which binds to the glycoprotein on Zaire ebolavirus (Ebola virus) to block its entry into host cells. Ansuvimab has been recently approved in the USA for the treatment of infection caused by Z. ebolavirus in adult and paediatric patients, including in neonates born to a mother who is RT-PCR positive for Z. ebolavirus infection, following the results of the PALM phase II/III trial. This article summarizes the milestones in the development of ansuvimab leading to this first approval for the treatment of infections caused by Ebola virus in adults and paediatric patients.

Automated summary

Ansuvimab, developed by Ridgeback Biotherapeutics, is a human monoclonal antibody approved in the USA for treating Zaire ebolavirus infection in both adult and paediatric patients. It blocks the entry of Ebola virus into host cells by binding to the virus glycoprotein.